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The generation of lipid products catalyzed by PI3K is critical for normal T cell homeostasis
and a productive immune response. PI3K can be activated in response to antigen receptor,
co-stimulatory, cytokine, and chemokine signals. Moreover, dysregulation of this pathway
frequently occurs in T cell lymphomas and is implicated in lymphoproliferative autoim-
mune disease. Akt acts as a central mediator of PI3K signals, downstream of which is the
mTOR pathway, controlling cell growth and metabolism. Members of the Foxo family of
transcription factors are also regulated by Akt, thus linking control over homing and migra-
tion of T cells, as well cell cycle entry, apoptosis, and DNA damage and oxidative stress
responses, to PI3K signaling. PTEN, ﬁrst identiﬁed as a tumor suppressor gene, encodes
a lipid phosphatase that, by catalyzing the reverse of the PI3K “reaction,” directly opposes
PI3K signaling. However, PTEN may have other functions as well, and recent reports have
suggested roles for PTEN as a tumor suppressor independent of its effects on PI3K signal-
ing.Through the use of models in which Pten is deleted speciﬁcally inT cells, it is becoming
increasingly clear that control over autoimmunity and lymphomagenesis by PTEN involves
multi-faceted functions of this molecule at multiple stages within theT cell compartment.
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INTRODUCTION
Class 1A PI3Ks are directly linked to lymphocyte activation mainly
through receptor tyrosine kinases, such as the antigen and cytokine
receptors (Engelman et al., 2006; Huang and Sauer, 2010; So and
Fruman, 2012). Class 1A PI3Ks, hereafter referred to as PI3K, are
comprised of a catalytic subunit of 110 kDa (of which there are
three isoforms) that generates phosphatidylinositol 3,4,5 phos-
phate (PIP3) from its main substrate phosphatidylinositol 4,5
phosphate (PIP2), and a regulatory subunit (of which there are
ﬁve isoforms). Pten encodes a protein with a lipid phosphatase
function that directly opposes PI3K signaling by dephosphory-
lating PIP3 at the 3′ position to generate PIP2. Cells lacking
PTEN have elevated levels of PIP3 and constitutive activation of
PI3K signaling pathways (Stambolic et al., 1998; Cantley and Neel,
1999). With increasing age, mice heterozygous for Pten develop
T cell lymphomas and cancers in multiple tissues, and develop a
lethal polyclonal autoimmune disorder, similar to that seen in Fas-
deﬁcient mice (Di Cristofano et al., 1998, 1999; Podsypanina et al.,
1999; Suzuki et al., 2001). Germline mutations in PTEN occur in
a group of autosomal dominant syndromes known as the PTEN
hamartoma tumor syndromes, which include Cowden syndrome,
Proteus syndrome, Proteus-like syndrome, and Bannayan–Riley–
Ruvalcaba syndrome, demonstrating the importance of PTEN as
a tumor suppressor. Consistent with this, genomic ampliﬁcation
and mutation of either PI3K or Akt has been reported in a large
number of cancers as well (Samuels et al., 2004; Lee et al., 2005;
Carpten et al., 2007; Jaiswal et al., 2009), although the role of PTEN
as a tumor suppressor is now believed to involvemore than its abil-
ity to oppose PI3K signaling. While disruption of regulation by
PTEN has the overt phenotype of cancer progression, PTEN also
plays an important role in maintaining T cell tolerance at multiple
stages within the T cell compartment.
ACTIVATION AND REGULATION OF PI3K CLASS 1A
IN T LYMPHOCYTES
Upon ligation of the T cell receptor (TCR) in the presence of
co-stimulatory molecules, PI3K recruitment and activation leads
to the production of lipid products which in turn recruit down-
stream PH-domain containing targets such as PDK1 and Akt
(see Figure 1). Ultimately, these events lead to activation of the
mTOR pathway and inactivation of members of the Foxo family,
inducing growth and proliferation of T cells and acquisition of
effector function (for review, see Engelman et al., 2006; Finlay and
Cantrell, 2010; So and Fruman, 2012). In the absence of PTEN,
TCR stimulation alone results in hyperactivation of the PI3K
pathway, resulting in effective cytokine production and prolifer-
ation independent of co-stimulation (Buckler et al., 2006). Thus,
put another way, negative regulation of PI3K signaling by PTEN
enforces the requirement for co-stimulation in naïve T cells. How-
ever, the notion that PI3K signaling is required for co-stimulation
to mediate its effects has been challenged by the generation of
mice which lack all isoforms of the regulatory subunit of class 1A
PI3K in T cells (Deane et al., 2007). T cells from these mice are
able to proliferate under co-stimulatory conditions in the absence
of detectable Akt signaling. These mice also maintained a normal
anti-viral response uponMHV infection, although in vivoThelper
function to B cell antibody responses was impaired. Whether the
relative lack of defects is due to the fact that lack of PI3K was
genetic, rather than acquired, is not known. However, these studies
indicate that potential therapies targeting PI3K for inﬂammatory
diseases and cancer may not compromise all aspects of cellular
immunity, and further suggest that PI3K signaling has specialized
functions in the context of T cell activation.
PI3K activation is critical for optimal responses of T cells to
cytokines which utilize the common gamma chain. For example,
www.frontiersin.org June 2012 | Volume 3 | Article 151 | 1
“ﬁmmu-03-00151” — 2012/6/13 — 21:07 — page 2 — #2
Newton andTurka Pten function in T cells
FIGURE 1 | PTEN/PI3K signaling in matureT cells. Class 1A PI3Ks are
activated by receptor tyrosine kinases that drive co-stimulatory, T cell receptor
(TCR), and cytokine signaling pathways. PTEN directly opposes PI3K signaling
by converting PI(3,4,5)P3 to PI(4,5)P2. Through their PH-domains, PDK1 and
Akt bind PIP3, enabling Akt to be phosphorylated by PDK1 on Ser308. Full
activation of Akt requires phosphorylation on Ser473 by mTORC2. Akt can
then target downstream substrates such as Foxos in the nucleus, leading
to their inactivation and export from the nucleus. This results in attenuation
of a Foxo-dependent gene program normally acting to promote pathways
involved in, but not limited to, T cell homeostasis (in resting T cells), apoptosis
(upon, for example, cytokine withdrawal), Treg induction, and homing to
secondary lymphoid organs (in circulating, naïve T cells). Akt also targets
TSC2 and Pras40 (not shown), negative regulators of mTORC1, allowing for
activation of mTORC1. Activation of S6K and 4EBPs by mTORC1 results in
increased protein translation, allowing growth and proliferation, and
upregulation of Hif-1α, important for glycolytic metabolism. Inhibitory
targeting of Bad and GSK3 also contribute to Akt’s effect on cell cycle,
survival and metabolism.
engagement of the IL-2R on activated T cells results in activa-
tion of the Jak/Stat pathway, as well as the PI3K and MAPK
pathways, and the combination of these signals is required for
the observed proliferation and cell survival in response to IL-2.
Thus, appropriate responses to TCR ligation and cytokines require
downregulation of PTEN, which is constitutively expressed in
naïve T cells. This normally occurs as a consequence of TCR
stimulation itself, which terminates detectable PTEN expression
within 24–48 h. The importance of this is demonstrated by
two ﬁndings. First, retroviral mediated “enforced” expression of
PTEN renders activated IL-2R+ T cells unable to fully respond
to IL-2 stimulation. Second, regulatory T cells, which normally
do not divide in response to IL-2 alone, have complete responses
and signaling to IL-2 restored solely by genetic ablation of Pten
(Bensinger et al., 2004; Walsh et al., 2006; Locke et al., 2009).
This demonstrates that control of PI3K through PTEN plays an
important role not only in modulating the degree of activation
signals within lymphocytes, but in maintaining traits of a speciﬁc
lineage.
PI3K-related signals can modulate ongoing responses as
well. Deletion of Pten, or expression of constitutively active
myristoylated-Akt, within the CD8+ T cell compartment inhibits
the development and survival of memory CD8+ T cells (Hand
et al., 2010). On the contrary, Akt is required for a transcriptional
program leading to upregulation of cytolytic effector, chemokine,
and adhesion molecules (Macintyre et al., 2011). Conditional
deletion of Pten using OX40-Cre has demonstrated that PTEN
plays a critical role in limiting the expansion of Tfh cells and
in maintaining control over GC reactions, indicating that T cell
intrinsic roles of PTEN are crucial for maintaining global lev-
els of tolerance (Rolf et al., 2010). Lastly, the promotion of iTreg
generation and maintenance by PD-L1 is associated with down-
regulation of Akt signaling and concomitant upregulation of
PTEN expression (Francisco et al., 2009). These examples all pro-
vide evidence that the balance of Akt signaling within multiple
stages of development and differentiation states helps determine
cellular fate.
PTEN also has been shown to play an important role in central
tolerance and in regulating proliferation of developing cells in the
thymus (Suzuki et al., 2001; Hagenbeek et al., 2004). In the absence
of IL-7R and pre-TCR signaling, loss of Pten allows cells to bypass
theβ-selection checkpoint, indicating that PI3K signaling is crucial
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for the ongoing development of early T cell precursors. Inter-
estingly, thymic cellularity and subset percentages are relatively
unperturbed prior to tumor development, which likely occurs at
the DP stage during thymic maturation, suggesting that secondary
events emerge in this context of Pten loss to promote transfor-
mation (discussed below; Hagenbeek et al., 2004; Hagenbeek and
Spits, 2008; Xue et al., 2008; Guo et al., 2011).
SIGNALING DOWNSTREAM OF Pten-PI3K-Akt: A CRITICAL
ROLE FOR Foxos
Members of the Foxo family of transcription factors play a critical
role in DNA damage and oxidative stress responses (Tran et al.,
2002; Miyamoto et al., 2007; Tothova et al., 2007; Choi et al., 2009)
and in preventing entry into cell cycle (Medema et al., 2000), acting
as bona ﬁde tumor suppressors as demonstrated in hematopoietic
and epithelial tissues (Coffer, 2003; Accili and Arden, 2004; Paik
et al., 2007). It is becoming increasingly appreciated that Foxos
play important roles within the T cell compartment as well, reg-
ulating homing (Fabre et al., 2008; Sinclair et al., 2008; Finlay
et al., 2009; Kerdiles et al., 2009; Finlay and Cantrell, 2010), sur-
vival (Hedrick, 2009; Kerdiles et al., 2009; Dejean et al., 2011),
and the development and function of effector and memory sub-
sets (Kerdiles et al., 2010; Ouyang et al., 2010; Rao et al., 2012).
In quiescent cells, Foxos are active within the nucleus, where
they maintain the pattern of chemokine and adhesion molecule
expression, and expression of the IL-7R, needed for the migra-
tion and survival of circulating T cells (Fabre et al., 2008; Finlay
et al., 2009; Kerdiles et al., 2010). Akt phosphorylation on Ser473,
mediated by mTORC2, is critical for Foxo inactivation, implicat-
ing mTOR in control over Foxos, and placing PTEN upstream
in this pathway. Importantly, mTORC2 has been shown to be
critical for the phenotype in models of PTEN loss. Prostate
cancer caused by conditional Pten deletion in prostate epithe-
lium requires mTORC2, and deletion of one copy of Rictor,
required for mTORC2 complex assembly and activity, was suf-
ﬁcient to protect Pten heterozygous mice from prostate cancer
(Guertin et al., 2009).
The role of Foxos in T cells was ﬁrst described using mice in
which retroviral gene-trap targeting of embryonic stem cells was
used to generate a null Foxo3 allele, although the authors could
not rule out the possibility that undetectable levels of a trun-
cated form of Foxo3 was produced (Lin et al., 2004). These mice
exhibited spontaneous lymphoproliferation andmulti-organ lym-
phocyte inﬁltration, indicating that Foxo3 is important for the
control of T cell tolerance and homeostasis. This hyper-activated
phenotype was correlated with decreased expression of IκBε and
IκBβ, leading to increased NF-κB activation. As IKKβ has been
shown to phosphorylate and inactivate Foxos (Hu et al., 2004),
this implicates Foxos in a critical negative feedback loop that may
serve to limit inﬂammatory responses in certain settings, and is
potentially important in the context of tumorswhichmaintain low
levels of Akt activation. Other studies using Foxo3-deﬁcient strains
did not ﬁnd the same immunological defects (Hosaka et al., 2004;
Dejean et al., 2009), attesting ﬁrst to the redundancy of members
of this family and, second, to the possibility of dominant-negative
effects of undetected Foxo3 gene products in the aforementioned
mice. T cell-speciﬁc loss of Foxo1 was shown to severely disrupt
T cell homeostasis, resulting in multi-organ lymphocyte inﬁl-
tration as well as exocrine pancreatitis and hind limb paralysis
(Kerdiles et al., 2010). This was attributed to a defect in both the
development and function of Foxp3+ regulatory T cells, and this
phenotype was exacerbated by combined deletion of Foxo1 and
Foxo3 (Kerdiles et al., 2010; Ouyang et al., 2010). More recently,
Foxo3a has been mechanistically linked to anergy induction in
T cells through upregulation of Sirt1 (Gao et al., 2012). IL-2 was
shown to reverse T cell anergy through the PI3K pathway by inac-
tivation of Foxos, which prevented transcriptional upregulation
of Sirt1.
In mouse embryonic ﬁbroblasts and lymphoid cells, growth
factor and cytokine withdrawal upregulates BH3-only pro-
apoptotic mediators Puma and Bim in a Foxo3a-dependent
manner that requires downregulation of PI3K/Akt signaling (You
et al., 2006). These ﬁndings strongly support the idea that impaired
downregulation of PI3K activity, as seen in T cells lacking PTEN,
results in survival effects and apoptotic resistance in response to
cytokine deprivation through inactivation of Foxo family mem-
bers. FasL has been shown to be another important target of
Foxo (Brunet et al., 1999). Given that Pten heterozygous mice dis-
play decreased sensitivity to Fas-mediated AICD, similar to lpr
and gld mice (Van Parijs and Abbas, 1996), constitutive inactiva-
tion of Foxos due to loss of PTEN is likely a partial mechanism
underlying the phenotype observed in these mice. Addition-
ally, the ﬁnding that a deﬁciency in Foxos is sufﬁcient to drive
the development of hemangiomas, similar to what is seen in
patients with Cowden disease and Bannayan–Zonana syndrome,
and thymic lymphomas, similar to mice with a T cell-speciﬁc
deletion of Pten, as well suggests that inactivation of Foxos
may be critical for the phenotype brought on by loss of Pten
(Paik et al., 2007).
LYMPHOMA AND DYSREGULATED IMMUNE FUNCTION IN
THE ABSENCE OF PTEN
Genetic studies in mice expressing conditional alleles of Pten
have been crucial for studying the tissue speciﬁc role of PTEN
in tumorigenesis. Deletion of Pten during hematopoiesis using
Mx-1-Cre results in myeloproliferative disease and transplantable
leukemia, and has shown that PTEN is required for maintaining
the hematopoietic stem cell (HSC) compartment (Yilmaz et al.,
2006; Lee et al., 2010). Similar to the Mx-1-Cre model of PTEN
loss, Vec-Cre-mediated PTEN loss, in which nearly 40% of fetal
liver HSCs were subject to deletion of Pten, led to impaired HSC
self-renewal and the development of a myeloproliferative disor-
der followed by leukemia (Guo et al., 2008). It is notable that this
phenotype shares striking similarity to mice in which all six alleles
of Foxo1/3a/4 were deleted by Mx-1-Cre (Tothova et al., 2007),
and to Foxo3a−/− mice (Miyamoto et al., 2007). Importantly,
this study reported the same t(14;15) chromosomal transloca-
tion (seen within a subset of human T-ALL), in all blast-crisis
samples analyzed from these mice, suggesting a critical genomic
destabilizing event potentially independent of PTEN’s role in con-
trolling PI3K/Akt signaling. Similarly, this translocation, involving
the c-myc and TCRα/δ loci and resulting in constitutively high lev-
els of c-myc, was found to recur with 100% incidence in T cell
lymphomas from mice in which Pten was deleted speciﬁcally
www.frontiersin.org June 2012 | Volume 3 | Article 151 | 3
“ﬁmmu-03-00151” — 2012/6/13 — 21:07 — page 4 — #4
Newton andTurka Pten function in T cells
in T cells (CD4-Cre × Ptenﬂ/ﬂ mice, hereafter referred to as
PTEN-T mice; Liu et al., 2010). Thus, well after T lineage com-
mitment in mice subject to lymphoma and lymphoproliferative
autoimmune disease, PTEN is critical to prevent the emergence
of the same genetic abnormality present in HSCs that corre-
lates with the selective pressure of these cells for the development
of leukemia.
A deﬁciency in Rag1 or TCRα prevented the t(14;15) transloca-
tion event in PTEN-T mice, but did not inhibit malignant trans-
formation, although lymphomagenesis developed with delayed
onset and was primarily restricted to the thymus (Liu et al.,
2010). Interestingly, mature T cells from 3-week-old PTEN-T
mice that had not undergone transformation, when transferred
into either immunocompetent or immunoincompetent recipi-
ents, did not develop a malignant phenotype throughout the
duration of the host’s life, suggesting that malignancy arises
within the thymus after a period of latency in these mice, con-
sistent with an earlier report demonstrating that transplanted
Pten−/− thymocytes gave rise to T cell lymphomas in immun-
odeﬁcient recipients (Hagenbeek and Spits, 2008). Supporting
this, PTEN-T mice thymectomized at 3 weeks of age did not
develop lymphoma, although later in life thesemice exhibited signs
of systemic autoimmunity. Thus, within distinct developmental
stages, PTEN is required for the prevention of lymphoma and
autoimmunity.
In the context of DNA damage, loss of PTEN enables cells to
bypass the normal G2/M checkpoint enforced by CHK1 as a result
of Akt-mediated CHK1 sequestration in the cytoplasm (Puc et al.,
2005). Akt has also been shown to promote prosurvival responses
following DNA double-strand breaks (DSBs; Bozulic et al., 2008).
It is possible that secondary mutations or other genetic alterations
occurred in Rag1−/− or TCRα−/− × PTEN-T mice as a result
of genetic instability due to PTEN loss, and that hyper-active Akt
maintains the survival of these cells that would normally undergo
apoptosis. Spectral karyotyping analyses, however, failed to detect
any chromosomal translocations in thesemice to support this idea.
Inductionof theNotchpathway inmalignant cells from thesemice,
however, was shown to increase cellular levels of c-myc, suggesting
that PI3K and c-myc cooperate in multiple models of PTEN loss to
promote lymphomagenesis and lymphoproliferative autoimmune
disorder.
Disruption of Foxo function has been shown to accelerate
c-myc-driven lymphomagenesis (Bouchard et al., 2007), and con-
stitutively active mutants of Foxo3a resistant to inactivation by
Akt directly repress multiple target genes of c-myc and block
c-myc-dependent proliferation and transformation (Bouchard
et al., 2004; Jensen et al., 2011). Together, this offers the possi-
bility that c-myc and PI3K cooperate in tumorigenesis through
inactivation of Foxos. Whether or not restoration of Foxo signal-
ing in mice lacking PTEN in T cells has an effect on metabolism,
survival, inﬁltrative capacity, lymphomagenesis, or the prevention
of autoimmunity remains to be seen.
A recent study in which Ptenﬂ/ﬂ × CD4-Cre mice were crossed
to PDK1ﬂ/ﬂ mice has shown that while lymphoma did not develop
in this model of T cell-speciﬁc Pten deletion, PDK1/Akt signaling
was dispensable for the survival, proliferation and differentiation
of T cell progenitors, and in vivo expansion of peripheral T cells
(Finlay et al., 2009). Themechanism for control of cellmetabolism
independent of PDK1 is unclear in these mice, although thymo-
cyte proliferation in the absence of PTEN was shown to require
RhoA-dependent pathways, and a dependence on c-myc, which
was recently shown to play a pivotal role in T cell metabolism
following activation (Wang et al., 2011), was not ruled out. Mice
which express a single hypomorphic PDK1 allele similarly pre-
vented a wide range of tumors when crossed to Pten heterozygous
mice, indicating that the requirement for PDK1 in the context
of tumor formation brought on by loss of PTEN is not limited
to its role in controlling migratory capacity of T cells (Bayas-
cas et al., 2005). Additionally, deletion of S6K1 in the Mx-1-Cre
model of Pten loss resulted in delayed development of leukemia,
indicating that an mTORC1-mediated pathway, in this context
shown to involve induction of a Hif-1α-dependent glycolytic
program, contributes to leukemogenesis in Pten-deﬁcient cells
(Tandon et al., 2011).
Akt-INDEPENDENT ROLES OF PTEN
PTEN nuclear function, independent of its lipid phosphatase
activity, has been shown to contribute to its tumor-suppressive
effects and, in particular, in maintaining genomic stability. Con-
trol of DNA stability and DSB repair has in part been attributed
to interaction of PTEN with an integral kinetochore protein,
CENP-C. Mutants originally identiﬁed in Cowden disease patients
demonstrated that the C-terminus of PTEN, but not the phos-
phatase domain, was required for interaction with centromeres
and with CENP-C, and that DNA instability and DSBs could be
prevented by a phosphatase-dead PTEN mutant which retained its
ability to bind to CENP-C (Shen et al., 2007). Additionally, nuclear
exclusion of PTEN, but not a phosphatase-inactive mutant, was
shown to impair the tumor-suppressive APC-CDH1 nuclear
complex, again demonstrating tumor-suppressive capability of
catalytically inactive PTEN (Song et al., 2011). Additional protein–
protein interactions within the nucleus, independent of PTEN cat-
alytic activity, have been shown to increase the activity and stability
of p53 (Li et al., 2006; Salmena et al., 2008), and upregulate expres-
sion of Rad51, an essential component of the DSB repair machin-
ery (Baker, 2007; Shen et al., 2007). A lysine to glutamate mutation
in PTEN (K289E) identiﬁed in a Cowden syndrome family, which
lead to a dramatic decrease in nuclear import without disrupt-
ing phosphatase activity or membrane localization of PTEN, as
well strongly supports the idea that nuclear PTEN can be critical
for tumor suppression independent of its role in opposing PI3K
signaling in certain contexts (Trotman et al., 2007; See Figure 2).
Inactivation of PTEN phosphatase activity is sufﬁcient to
abrogate its tumor-suppressive effects, emphasizing the impor-
tance of PTEN’s role in downregulation of PI3K signaling. This
has been demonstrated by a subset of Cowden disease patients
that harbor a missense mutation at a cysteine residue (C124) crit-
ical for phosphatase activity. A C124S mutant has been shown to
form a stable complex with PIP3, potentially protecting it from
dephosphorylation by other lipid phosphatases to account for
higher cellular levels of PIP3 compared to conditions in which
PTEN is completely absent (Myers et al., 1998). As well, the impor-
tance of Akt activity in tumor development induced by loss of
PTEN has been reported in a number of studies (Stiles et al., 2002;
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FIGURE 2 | Molecular and phenotypic consequences of loss of PTEN
phosphatase-dependent and -independent functions during
hematopoiesis and within theT cell compartment. Loss of PTEN
phosphatase activity results in increased levels of PIP3, causing
hyperactivation of the Akt pathway and subsequent activation of the mTOR
pathway, and inactivation of the Foxo family of transcription factors.
Disruption of PTEN phosphatase-independent function accounts for loss of
much of its nuclear activity, compromising genetic stability and DSB repair,
leading to chromatid breaks and translocations. That mature T cells do not
undergo transformation, and that lymphoma in T cell-speciﬁc PTEN knockout
mice is of thymic origin, suggests that PTEN phosphatase-independent
function contributes less to the phenotype at the matureT cell stage, and that
loss of T cell tolerance can likely be attributed to loss of PTEN phosphatase
activity. Whether depletion of hematopoietic stem cells (HSCs) and
development of leukemia stem cells (LSCs), as well lymphomagenesis,
depends on the absence of PTEN phosphatase activity (which likely maintains
survival of genetically aberrant cells), PTEN phosphatase-independent activity
(promoting genetic instability), or both, remains an open question.
Bayascas et al., 2005; Chen et al., 2006). Constitutive Akt activa-
tion in T cells and thymocytes has been shown to be sufﬁcient to
drive autoimmunity and lymphoma (Rathmell et al., 2003) and
thymomas (Malstrom et al., 2001), respectively, and bone marrow
chimera experiments have demonstrated that enforced expression
of constitutively active Akt in HSCs was sufﬁcient for the devel-
opment of myeloproliferative disease, T cell lymphoma, or AML
(Kharas et al., 2010).
PTEN-T mice crossed onto the Rag1−/− background, which
do not harbor the t(14;15) translocation, potentially serve as an
example in which Akt signaling is not sufﬁcient to drive cancer
progression (Liu et al., 2010). In vitro studies using malignant
cells from these mice demonstrated a dependence on Notch,
suggesting that Akt at the very least must cooperate with other
oncogenic pathways to allow tumor growth in this model, similar
to what has been suggested in an MMTV-myrAkt breast cancer
model with respect to tumorigenesis induced by loss of PTEN
(Blanco-Aparicio et al., 2007). In contrast to this, in a model of
Notch-induced tumorigenesis, genetic loss of Pten induced an
oncogene addiction switch that rendered T-ALL cells resistant to
Notch inhibition through GSIs and dependent on PI3K/Akt sig-
naling to maintain tumor growth (Palomero et al., 2007). Thus,
the reliance on Akt signaling differs among models of PTEN loss.
This idea is perhaps emphasized by the observation that PTEN-
T mice, regardless of whether the t(14;15) translocation event
occurs, maintain constitutively high levels of c-myc.
The reliance on c-myc in the context of PTEN loss remains an
important question. In tumors driven by inducible c-myc acti-
vation in a zebraﬁsh model of T-ALL, constitutive activation of
the Akt pathway through genetic disruption of Pten or transgenic
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expression of Akt2 rendered cells in this model independent of
c-myc for tumor progression (Gutierrez et al., 2011). Conversely,
conditional genetic disruption of both Pten and c-myc in mice,
while still subject to myeloproliferative and lymphoproliferative
disorders, prevented the development of hematopoietic malig-
nancies, highlighting an important dependence on c-myc in this
context of PTEN loss (Zhang et al., 2011). Whether loss of PTEN
allows the survival of cells that, through other mechanisms, have
acquired genetic aberrations, such as translocations resulting in
constitutive c-myc, or whether PTEN, independent of its role in
PI3Kdownregulation, prevents genetic instability that collaborates
with dysregulation of PI3K to allow cancer progression, remains an
open question that needs to be addressed in a context-dependent
manner, with consideration of what function of PTEN is lost,
changes in levels of expression, and in which tissues abnormal
growth originates.
FUTURE DIRECTIONS
Pten is the one of the most frequently mutated or lost genes in
human cancer. Given the emerging roles of PI3K in immune
system regulation, it is possible that PTEN is also playing a
prominent role in the prevention of autoimmune disease and
inﬂammatory/lymphoproliferative syndromes. The ﬁnding that
PTEN did not play a role in lymphomagenesis in mature T cells
from mice which lack PTEN speciﬁcally in T cells suggested that
PTENhas a speciﬁc function inpreventing lymphomawithin adis-
tinct time frame in this compartment. That these non-malignant
T cells were able to provoke autoimmunity demonstrates that well
beyond the stage at which Pten is required for prevention of lym-
phomagenesis in this model, PTEN plays a critical role in the
maintenance of T cell tolerance. It will be important to deter-
mine which biochemical requirements PTEN fulﬁlls in each stage
of protection, and whether these requirements are distinct within
different stages from cells of the same lineage, or whether lack
of particular features leads to different outcomes depending on
developmental stage. Given the importance of PI3K signaling in
both normal immunity and the development of cancer, it will
be interesting to see how closely PTEN’s role as a lipid phos-
phatase is tied to prevention of disease, and how integral PI3K
signaling remains throughout disease progression. Uncovering
the speciﬁc biochemical functions of PTEN within these contexts
will be key to the development of targeted therapies for the pre-
vention and treatment of T cell malignancies and autoimmune
disease.
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